Top Healthcare Software Sales Companies in 2026: Where the Growth Is

There's a statistic I keep coming back to: US hospitals spend roughly 4-6% of their operating revenue on IT. Banks spend 7-10%. Retailers spend 3-5% but on a much larger and more modern technology stack. Healthcare is behind, and that gap represents an enormous amount of future spending.

That's the macro case for healthcare software sales. The micro case, the one that actually determines whether you'll be happy and successful at a specific company, is more nuanced. Not every healthcare software company is positioned to capture that spending. And the ones that are positioned well aren't necessarily the ones that show up first on a Google search.

I've spent a lot of time analyzing this market, and I want to share what I think matters, with the caveat that markets shift and any analysis is a snapshot, not a prediction.

A Note on How This Market Differs

Before getting into specific companies, it's worth pausing on something that trips up a lot of people who come from device or pharma sales.

Healthcare software sales cycles are measured in quarters, not weeks. A typical enterprise deal with a health system involves 6-14 months of stakeholder management, procurement review, IT security assessment, and budget approval. Some deals take longer. I've seen 18-month cycles for large platform deployments.

The buyer isn't a physician. It's usually a CIO, CMIO, VP of IT, or CFO. Sometimes it's a committee. The conversation centers on integration complexity, data migration, ROI timelines, and change management. Clinical value matters, but it's one input among many.

This has implications for compensation. Base salaries tend to run higher than device or pharma ($95K-$135K is typical for experienced enterprise reps), but the variable component is structured around annual or semi-annual targets rather than monthly commissions. You need to be comfortable with a longer feedback loop on your performance.

With that context, here's where I see the market.

Veeva Systems: Dominant, But Approaching a Ceiling

Veeva has achieved something rare in enterprise software: near-monopoly status in their core market. Their CRM and content management platforms are the default for life sciences companies. Once a pharmaceutical company is on Veeva, switching costs make it nearly impossible to leave.

From a sales perspective, that dominance creates a specific kind of role. You're not doing a lot of net-new logo acquisition in the traditional sense. The large pharma companies are already clients. The work is expansion: selling additional modules, moving clients from Vault to newer platforms, and pushing into adjacent use cases like clinical trial management and regulatory submissions.

This is good if you value predictability. Revenue is recurring, relationships are long-term, and the base of business is stable. Compensation including equity has been strong, though Veeva's stock growth has moderated compared to the explosive years.

Where I'd exercise caution: Veeva's growth rate is decelerating. Not declining; decelerating. The large pharma accounts are largely penetrated. Growth is coming from mid-market biotech and from new product categories. Those are real opportunities, but they require more effort than the land-and-expand motion that built the company. If you're joining Veeva expecting the growth trajectory of 2019, you should adjust your expectations.

Epic: Important to Understand, But Not a Sales Role

I'm including Epic because people always ask about them, but I want to be precise: Epic doesn't have a traditional field sales organization.

They dominate the EHR market. Most large US health systems run on Epic. But their commercial model is built around implementation, consulting, and account management rather than outbound sales. Their growth comes from expanding within existing clients and from the remaining health systems that haven't adopted an enterprise EHR.

If you want to work at Epic, it's a great company with a distinctive culture. But if you're looking for a sales role in the healthcare software space, Epic isn't where to look. The sales opportunities in the EHR ecosystem are at companies that build applications on top of Epic, integrate with Epic, or compete with Epic in specific verticals.

That's an important distinction. The "Epic ecosystem" of third-party vendors is large and growing, and many of those companies are actively hiring sales teams. If you understand how Epic works and can speak the language, that knowledge is valuable at dozens of other companies.

Health Catalyst: Interesting, With Some Caveats

Health Catalyst occupies a niche I find genuinely compelling: healthcare data analytics. They help health systems make sense of the enormous amounts of clinical and operational data they generate but rarely use effectively.

The sales motion is consultative and complex. You're selling to senior executives who may or may not understand what a data platform can do for them. In some conversations, you're educating the buyer on the problem before you can sell the solution. That requires patience and a specific kind of credibility.

I have mixed feelings about recommending Health Catalyst broadly. The product is well-regarded. The problem they solve is real and growing. But the company has gone through some turbulence, including leadership changes and a stock price that's been volatile. For an experienced enterprise seller who understands healthcare operations and can navigate ambiguity, it could be a great fit. For someone looking for a stable, predictable environment, I'd want to understand more about the current internal dynamics before committing.

Doximity: A Different Model Entirely

Doximity doesn't fit neatly into the "healthcare software" category, but I think it's important to include because they've built something unusual: a platform that physicians actually choose to use.

Their business model monetizes physician attention through pharmaceutical advertising and recruitment tools. If you're on the sales team, your clients are pharma marketing departments and hospital talent acquisition teams, not the physicians themselves.

The role is closer to digital advertising sales than traditional healthcare software sales. The metrics are impressions, engagement rates, and campaign ROI rather than platform deployments and SaaS contracts. That's a meaningful difference in daily experience.

Doximity is a strong company with good economics. But I'd encourage anyone considering it to be clear-eyed about what the job actually involves. If you want to sell software to health systems, Doximity isn't that. If you want to sell digital marketing solutions to pharma companies, it could be an excellent fit.

The Growth-Stage Companies

This is where my analysis gets more speculative, which I want to acknowledge upfront. Growth-stage companies are inherently less predictable than established players, and my observations are based on market signals rather than the kind of long track record you can evaluate at a Veeva or Epic.

That said, there are several categories where I'm seeing genuine commercial traction.

Revenue cycle management automation. Health systems lose billions annually to billing errors, denied claims, and manual processes. Companies building AI-driven RCM tools have a straightforward value proposition: we save you money. When you can demonstrate measurable ROI in the first 90 days, the sales cycle compresses significantly. I've heard of companies in this space closing six-figure deals in under four months, which is fast by health system standards.

Remote patient monitoring. The technology has existed for years, but reimbursement was always the bottleneck. CMS has been steadily expanding coverage for RPM services, and that's creating real purchasing demand. The companies that have figured out both the technology and the billing workflow are starting to scale commercially.

Clinical AI tools. I'm cautious about this category because there's been more hype than substance in clinical AI. But there are a handful of companies, particularly in radiology and pathology, that have FDA clearances, published clinical evidence, and actual hospital contracts. The sales process for these tools is long and evidence-intensive, but the early movers are building defensible positions.

Interoperability platforms. As health systems increasingly need to share data across organizations, companies building interoperability infrastructure are finding buyers. This is a less glamorous category, but the revenue is sticky and the switching costs are high once you're embedded.

The risk with any growth-stage company is real. I've watched companies with promising products and strong initial traction stall because they couldn't scale their go-to-market, or because a larger competitor copied their approach, or because their funding didn't materialize. If you're evaluating a growth-stage opportunity, look carefully at the funding runway, the customer retention metrics, and whether the sales they've made so far required heroic effort from the founders or whether a repeatable sales process exists.

The Hiring Challenge in This Space

Something I think is worth noting, particularly for companies reading this: the talent shortage in healthcare software sales is real and getting worse.

The ideal candidate has enterprise SaaS sales experience and healthcare domain expertise. Those two skill sets rarely overlap. Companies end up compromising in one direction or the other, and both compromises have costs. The enterprise software rep who doesn't understand healthcare takes 6-9 months to become credible with buyers. The healthcare sales rep who doesn't understand enterprise software struggles with the sales methodology and CRM discipline that technology companies expect.

This gap is one reason why some healthcare software companies are exploring contract sales arrangements for specific use cases, particularly during product launches or geographic expansion where they need experienced people quickly. MDliaison works with healthcare software companies to connect them with sales professionals who have relevant healthcare domain expertise and can contribute on a flexible basis.

Compensation Patterns

Compensation in healthcare software sales varies more than in device or pharma, partly because the category is broader and partly because company stage matters enormously.

At established companies like Veeva, total compensation for senior account executives can reach $250K-$280K including equity. At mid-stage companies with proven products and revenue, $175K-$225K is a reasonable range. At early-stage companies, cash compensation might be lower ($130K-$170K total), but the equity component could be worth substantially more if the company succeeds.

The variable that matters most isn't the company's stated OTE. It's whether quota is achievable. I've seen companies post $250K OTE numbers where fewer than 30% of the sales team hits quota. That $250K figure is misleading if the realistic expectation is $180K. Ask to see quota attainment data during the interview process. If a company won't share it, that tells you something.

Our medical sales compensation benchmarks provide additional context on how healthcare software sales compensation compares across verticals.

Evaluating Opportunities in This Space

If I had to distill my analysis into a framework, it would focus on three questions:

Does the product solve a problem the buyer already knows they have? If you're selling a solution that requires you to first convince the buyer they have a problem, your sales cycle will be long and your close rate will be low. The best healthcare software products address pain that's already felt.

Is the company's go-to-market motion repeatable? Early-stage companies often make their first sales through founder relationships and one-off deals. That's fine for getting started, but if you're joining as a sales hire, you need to know whether there's a scalable process or whether you're expected to figure it out from scratch.

What does the competitive landscape look like in two years? Healthcare software markets tend to consolidate. If there are fifteen companies selling similar products today, there will be five in two years. Make sure you're joining one of the five.

Those questions won't guarantee you make the right choice. But they'll help you avoid the obvious mistakes.